Promotion or suppression of experimental metastasis of B16 melanoma cells after oral administration of lapachol

Toxicology and Applied Pharmacology

Volumn 229, Issue 2, 2008, Pages 232-238

  Maeda, Masayo ^a   Murakami, Manabu ^a   Takegami, Tsutomu ^a   Ota, Takahide ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

B16 melanoma; Cancer; Herbal medicines; Lapachol; Metastasis; Vitamin K antagonist; Warfarin

Indexed keywords

LAPACHOL; MENADIONE; PROTEIN C; WARFARIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG MEGADOSE; IN VITRO STUDY; LOW DRUG DOSE; MALE; MELANOMA B16; MELANOMA CELL; METASTASIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PROTHROMBIN TIME; SINGLE DRUG DOSE; T LYMPHOCYTE; TUMOR PROMOTION;

ADMINISTRATION, ORAL; ANIMALS; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; NAPHTHOQUINONES; NEOPLASM METASTASIS; VITAMIN K;

MURINAE; MUS;

EID: 43449109763     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2008.01.008     Document Type: Article

References (50)

1. Agostino D., Cliffton E.E., and Girolami A. Effect of prolonged coumadin treatment on the production of pulmonary metastases in the rat. Cancer 19 (1966) 284-288
2. Balassiano I.T., De Paulo S.A., Henriques Silva N., Cabral M.C., and da Gloria da Costa Carvalho M. Demonstration of the lapachol as a potential drug for reducing cancer metastasis. Oncol. Rep. 13 (2005) 329-333
3. Bick R.L. Coagulation abnormalities in malignancy: a review. Semin. Thromb. Hemost. 18 (1992) 353-372
4. Block J.B., Serpick A.A., Miller W., and Wiernik P.H. Early clinical studies with lapachol (NSC-11905). Cancer Chemother. Rep. 4 (1974) 27-28 (Part 2)
5. Bobek V., and Kovarik J. Antitumor and antimetastatic effect of warfarin and heparins. Biomed. Pharmacother. 58 (2004) 213-219
6. Broekmans A.W., Bertina R.M., Loeliger E.A., Hofmann V., and Klingemann H.G. Protein C and the development of skin necrosis during anticoagulant therapy. Thromb. Haemost. 49 (1983) 251
7. Brown J.M. A study of the mechanism by which anticoagulation with warfarin inhibits blood-borne metastases. Cancer Res. 33 (1973) 1217-1224
8. Butler T.P., and Gullino P.M. Quantitation of cell shedding into efferent blood of mammary adenocarcinoma. Cancer Res. 35 (1975) 512-516
9. Cliffton E.E., and Agostino D. Effect of inhibitors of fibrinolytic enzymes on development of pulmonary metastases. J. Natl. Cancer Inst. 33 (1964) 753-763
10. Cliffton E.E., Agostino D., and Minde K. The effect of hyperlipemia on pulmonary metastases of Walker 256 carcinosarcoma in the rat. Cancer Res. 21 (1961) 1062-1067
11. Cranenburg E.C., Schurgers L.J., and Vermeer C. Vitamin K: the coagulation vitamin that became omnipotent. Thromb. Haemost. 98 (2007) 120-125
12. Eisenberg D.M., Davis R.B., Ettner S.L., Appel S., Wilkey S., Van Rompay M., and Kessler R.C. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 280 (1998) 1569-1575
13. Engell H.C. Cancer cells in the circulating blood. Acta Chir. Scand. 201 (1955) 9-70 (Suppl.)
14. Fernandez J.A., Xu X., Liu D., Zlokovic B.V., and Griffin J.H. Recombinant murine-activated protein C is neuroprotective in a murine ischemic stroke model. Blood Cells Mol. Diseases 30 (2003) 271-276
15. 125I-5-iodo-2′-deoxyuridine. J. Natl. Cancer Inst. 45 (1973) 773-782
16. Glaves D. Correlation between circulating cancer cells and incidence of metastases. Br. J. Cancer 48 (1983) 665-673
17. Goldblatt S.A., and Nadel E.M. Cancer cells in the circulating blood: a critical review II. Acta Cytol. 9 (1965) 6-20
18. Griffin J.H., Evatt B., Zimmerman T.S., Kleiss A.J., and Wideman C. Deficiency of protein C in congenital thrombotic disease. J. Clin. Invest. 68 (1981) 1370-1373
19. Hafizi S., and Dahlback B. Gas6 and protein S. Vitamin K-dependent ligands for the Axl receptor tyrosine kinase subfamily. FEBS J. 273 (2006) 5231-5244
20. Hejna M., Raderer M., and Zielinski C.C. Inhibition of metastases by anticoagulants. J. Natl. Cancer Inst. 91 (1999) 22-36
21. Hilgard P., and Maat B. Mechanism of lung tumour colony reduction caused by coumarin anticoagulation. Eur. J. Cancer 15 (1979) 183-187
22. Hoult J.R.S., and Paya M. Pharmacological and biochemical actions of simple coumarins: natural products with therapeutic potential. Gen. Pharmacol. 27 (1996) 713-722
23. Jakobisiak M., Lasek W., and Golab J. Natural mechanisms protecting against cancer. Immunol. Lett. 90 (2003) 103-122
24. Kumar N.B., Allen K., and Bell H. Perioperative herbal supplement use in cancer patients: potential implications and recommendations for presurgical screening. Cancer Control 12 (2005) 149-157
25. LaRosa S.P., Opal S.M., Utterback B., Yan S.C.B., Helterbrand J., Simpson A.J.H., Chaowagul W., White N.J., and Fisher J.C.J. Decreased protein C, protein S, and antithrombin levels are predictive of poor outcome in Gram-negative sepsis caused by Burkholderia pseudomallei. Int. J. Infect. Dis. 10 (2006) 25-31
26. McCulloch P., and George W.D. Warfarin inhibition of metastasis: the role of anticoagulation. Br. J. Surg. 74 (1987) 879-883
27. Mehlen P., and Puisieux A. Metastasis: a question of life or death. Nat. Rev., Cancer 6 (2006) 449-458
28. Miller L.G. Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. Arch. Intern. Med. 158 (1998) 2200-2211
29. Mosnier L.O., Zlokovic B.V., and Griffin J.H. The cytoprotective protein C pathway. Blood 109 (2007) 3161-3172
30. Mousa S.A., Linhardt R., Francis J.L., and Amirkhosravi A. Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin. Thromb. Haemost. 96 (2006) 816-821
31. Nakano T., Matsui T., and Ota T. Benzyl-alpha-GalNAc inhibits sialylation of O-glycosidic sugar chains on CD44 and enhances experimental metastatic capacity in B16BL6 melanoma cells. Anticancer Res. 16 (1996) 3577-3584
32. Norred C.L., and Brinker F. Potential coagulation effects of preoperative complementary and alternative medicines. Altern. Ther. Health Med. 7 (2001) 58-67
33. Ota T., Tanino M., Kohno H., Funamoto H., and Odashima S. Isolation and characterization of a low metastatic variant from EL-4 mouse T-lymphoma. Clin. Exp. Metastasis 10 (1992) 297-308
34. Ota T., Maeda M., Matsui T., Kohno H., Tanino M., and Odashima S. Inhibition of metastasis by a dialysable factor in fetal bovine serum in B16 melanoma cells. Cancer Lett. 110 (1996) 201-205
35. Ota T., Maeda M., Tatsuka M., Matsui T., Tanino M., and Tanaka T. Decrease of metastatic ability after selection for intravasating ability in Lewis lung carcinoma (3LL) cell line. Cancer Lett. 139 (1999) 105-108
36. Preusch P.C., and Suttie J.W. Lapachol inhibition of vitamin K epoxide reductase and vitamin K quinone reductase. Arch. Biochem. Biophys. 234 (1984) 405-412
37. Rao K.V., McBridge T.J., and Oleson J.J. Recognition and evaluation of lapachol as an antitumor agent. Cancer Res. 28 (1968) 1952-1954
38. Rickles F.R., Levine M., and Edwards R.L. Hemostatic alterations in cancer patients. Cancer Metastasis Rev. 11 (1992) 237-248
39. Ryan J.J., Ketcham A.S., and Wexler H. Reduced incidence of spontaneous metastases with long-term Coumadin therapy. Ann. Surg. 168 (1968) 163-168
40. Sandberg A.A., Moore G.E., Crosswhite L.H., and Schubarg J.R. The frequency of tumor cells in the bone marrow and blood. Cancer 11 (1958) 1180-1186
41. Sieber S.M., Mead J.A., and Adamson R.H. Pharmacology of antitumor agents from higher plants. Cancer Treat. Rep. 60 (1976) 1127-1139
42. Srinivasan A.F., Rice L., Bartholomew J.R., Rangaswamy C., La Perna L., Thompson J.E., Murphy S., and Baker K.R. Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch. Intern. Med. 164 (2004) 66-70
43. Stevenson J.L., Varki A., and Borsig L. Heparin attenuates metastasis mainly due to inhibition of P- and L-selectin, but non-anticoagulant heparins can have additional effects. Thromb. Res. 120 (2007) S107-S111
44. Stirling Y. Warfarin-induced changes in procoagulant and anticoagulant proteins. Blood Coagul. Fibrinolysis 6 (1995) 361-373
45. Sun N.C., McAfee W.M., Hum G.J., and Weiner J.M. Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients. Part I. Coagulation studies. Am. J. Clin. Pathol. 71 (1979) 10-16
46. Tagalakis V., Blostein M., Robinson-Cohen C., and Kahn S.R. The effect of anticoagulants on cancer risk and survival: systematic review. Cancer Treat. Rev. 33 (2007) 358-368
47. Tait R.C., Walker I.D., Islam S.I., McCall F., Conkie J.A., Wight M., Mitchell R., and Davidson J.F. Protein C activity in healthy volunteers-influence of age, sex, smoking and oral contraceptives. Thromb. Haemost. 70 (1993) 281-285
48. Trinchieri G. Biology of natural killer cells. Adv. Immunol. 47 (1989) 187-376
49. Vigano S., Mannucci P.M., Solinas S., Bottasso B., and Mariani G. Decrease in protein C antigen and formation of an abnormal protein soon after starting oral anticoagulant therapy. Br. J. Haematol. 57 (1984) 213-220
50. Weiss L., Mayhew E., and Rapp D.G. Metastatic inefficiency in mice bearing B16 melanomas. Br. J. Cancer 45 (1982) 44-53